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Although tissue inhibitor of metalloproteinase-2 (TIMP-2) is known
to be not only an inhibitor of matrix metalloproteinases (MMP) but
also a cofactor for membrane-type 1 MMP (MT1-MMP)-mediated
MMP-2 activation, it is still unclear how TIMP-2 regulates MMP-2
activation and cleavage of substrates by MT1-MMP. In the present
study we examined the levels of cell-surface MT1-MMP, MMP-2
activation and cleavage of MT1-MMP substrates in 293T cells trans-
fected with the MT1-MMP and TIMP-2 genes. Co-expression of TIMP-2
at an appropriate level increased the level of cell-surface MT1-MMP,
both the TIMP-2-bound and free forms, and generated processed MMP-
2 with gelatin-degrading activity. In contrast, MT1-MMP substrates
testican-1 and syndecan-1 were cleaved by the cells expressing MT1-
MMP, which was inhibited by TIMP-2 even at levels that stimulate
MMP-2 activation. These results suggest that TIMP-2 environment
determines MT1-MMP substrate choice between direct cleavage of its
own substrates and MMP-2 activation. (Cancer Sci 2007; 98: 563–568)
MMP are a family of Zn2+-dependent enzymes that areknown to cleave extracellular matrix proteins under
normal and pathological conditions.(1–3) Presently, at least 28
mammalian MMP have been identified by cDNA cloning, and
they can be subgrouped into soluble MMP and MT-MMP.(3,4)
Although important in the degradation of the extracellular matrix,
growing evidence has implicated MMP in specific processing
resulting in activation or degradation of cell surface receptors
and ligands.(5) Cancer cells make use of MMP for invasion and
metastasis. The invading cells are forced to proliferate within
embedded dense three-dimensional matrix composed largely
of type I collagen or cross-linked fibrin. MT1-MMP has been
thought to play a major role in this step.(5)
The MMP family is balanced by a family of TIMP. TIMP-2
preferentially complexes with pro-MMP-2,(6) and plays a pivotal
role in the MT1-MMP-mediated activation process.(7–10) The
active form of MT1-MMP first binds TIMP-2 through its catalytic
domain, thus docking soluble TIMP-2 to the cell surface. This
TIMP-2–MT1-MMP complex subsequently functions as a receptor,
allowing pro-MMP-2 to form a ternary complex through the
interaction of its carboxyl-terminal domain and the carboxyl-
terminal domain of TIMP-2. The propeptide of pro-MMP-2 is
cleaved between Asn37 and Leu38 by an adjacent TIMP-2-free
MT1-MMP, generating an activated intermediate form that is
further processed to the fully activated form by an intermolecular
autocleavage when present at a sufficiently high concentration
on the cell surface. When TIMP-2 exists in excess relative to MT1-
MMP, the first step of this activation process is blocked.(7,8,11–13)
MMP-2 is involved in various pathological events, including
tumor invasion and metastasis, by degrading type IV and V
collagens, laminin, fibronectin, elastin and so on.(1,2) An active
form of MMP-2 has been frequently detected in tumor tissues,
in which MT1-MMP is always expressed.(5) Thus, MT1-MMP
is thought to contribute to tumor invasion and metastasis by
activating MMP-2. In addition to MMP-2 activation, MT1-
MMP directly digests various ECM components and cell surface
molecules, which also have physiologically and pathologically
essential functions.(5) TIMP-2 is essential for facilitating MT1-MMP
processing of MMP-2 and we closely compared this here with the
roles of TIMP-2 in cleavage of other substrates by MT1-MMP.
Materials and methods
Cell culture. Human embryonic kidney 293T cells were obtained
from American Type Culture Collection (Rockville, MD, US) and
cultured in DMEM (Sigma, St Louis, MO, USA) supplemented
with 5% fetal calf serum.
Plasmid. Expression plasmids for MT1-MMP, FLAG-tagged
MT1-MMP (MT1-MMP-FLAG), TIMP-2, FLAG-tagged testican-
1 (testican-1-FLAG) and syndecan-1 were constructed in pEAK8
vector (EdgeBio Systems, Gaithersburg, MD, USA) as described
previously.(14–16)
Cell surface biotinylation. Cell surface labeling with biotin and
immunoprecipitation were carried out as described previously.(17)
Briefly, expression plasmid for MT1-MMP-FLAG (700 ng) was
cotransfected with increasing amounts of TIMP-2 plasmid into
293T cells cultured in a 35 mm-diameter dish coated with poly
l-lysine. At 48 h after transfection, cells were incubated with PBS
containing 0.5 µg/mL Biotin Sulfo-OSu (Wako Pure Chemical
Industries, Osaka, Japan) for 30 min at 4°C. The cells were then
lysed and were subjected to immunoprecipitation with anti-FLAG
M2 antibody-conjugated agarose beads. The immunoprecipitated
material was separated by 12% SDS-PAGE, and then blotted
with IRDye 800-conjugated streptavidin (Rockland, Gilbertsville,
PA, USA) and anti-FLAG M2 antibody (Sigma) conjugated
with Alexa Fluor 680 (Molecular Probes, Eugene, OR, USA).
IRDye 800 and Alexa Fluor 680 were detected using a LI-COR
Odyssey IR imaging system (Lincoln, NE, USA).
Western blotting. Anti-MT1-MMP monoclonal antibody (113-
5B7) and anti-TIMP-2 monoclonal antibody (11-1403) were gifts
from Daiichi Fine Chemical Co. (Takaoka, Japan). MT1-MMP
and TIMP-2 in cell lysates were detected by western blotting
using anti-MT1-MMP antibody and anti-TIMP-2 antibody,
respectively.
TIMP-2 binding assay. Recombinant TIMP-2 (a gift from Daiichi
Fine Chemical Co.) was labeled with Alexa Fluor 680. Expre-
ssion plasmid for MT1-MMP (100 ng) was cotransfected with
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increasing amounts of TIMP-2 plasmid into 293T cells cultured
in 48-well microplates. At 48 h after transfection, cells were
incubated with labeled TIMP-2 (10−8 M) for 1 h, and then
washed three times with PBS. Binding of labeled TIMP-2 was
monitored using an Odyssey IR imaging system.
Zymography and gelatin degradation assay. Pro-MMP-2 super-
natant was prepared from MMP-2-transfected 293T cells as
described previously.(13) 293T cells cultured in 48-well micro-
plates were cotrasnfected with MT1-MMP and TIMP-2 plasmids
in duplicate, cultured for 48 h, and were incubated with 100 µL
pro-MMP-2 for 1 h. Supernatants and cells dissolved in 100 µL
SDS-PAGE sample buffer were analyzed by gelatin zymography
using Alex Fluor 680-labeled gelatin.(17) Supernatants (10 µL)
were examined for gelatin-degrading activity by incubating with
an equal volume of Alex Fluor 680-labeled gelatin (2 µg/mL)
for 1 h. Cells were incubated with 100 µL labeled gelatin
(1 µg/mL) in DMEM for 1 h. Labeled gelatin was separated on
10% SDS-PAGE and monitored using an Odyssey IR imaging
system.
Testican-1 cleavage. Testicans, including testican-1, interfere
with MT1-MMP-mediated MMP-2 activation when coexpressed
with MT1-MMP,(15) and testican-1 is cleaved by cells expressing
MT1-MMP (Sato, H., unpublished data). Expression plasmid
for testican-1-FLAG (2 µg) was transfected into 293T cells in
35 mm diameter dishes and culture medium replaced with 2 mL
serum-free DMEM after 48 h. Conditioned medium was harvested
after 24 h, diluted 10-fold with fresh serum-free DMEM, and
used as testican-1-FLAG sample. 293T cells cultured in 35 mm-
diameter dishes were cotransfected with MT1-MMP (700 ng)
and increasing amounts of TIMP-2 plasmid, and cultured for
48 h. Testican-1-FLAG (1 mL) was incubated with transfected
cells for 3 h, concentrated with trichloroacetic acid, and analyzed
by western blotting using anti-FLAG M2 antibody.
Syndecan-1 shedding. Expression plasmid for syndecan-1
(500 ng) was cotransfected with MT1-MMP (700 ng) and
increasing amounts of TIMP-2 plasmid into 293T cells cultured
in 35-mm dishes. Culture medium was replaced 48 h after trans-
fection with 1 mL serum-free DMEM, and cells were incubated
for a further 24 h. Supernatants were examined by slot blot analysis
using antisyndecan-1 antibody as described previously.(14)
Results
Cell-surface MT1-MMP. To analyze the level of cell-surface
MT1-MMP and TIMP-2 that bound to MT1-MMP, cell-surface
labeling with biotin and immunoprecipitation were carried out.
The cell-surface level of transfected MT1-MMP was greatly
increased by coexpression of TIMP-2 (Fig. 1). TIMP-2 was
coprecipitated with MT1-MMP in a dose-dependent manner, but
the ratio of coprecipitated TIMP-2 to MT1-MMP was not
constant. Surface MT1-MMP of cells expressing a low level of
TIMP-2 showed a lower ratio of coprecipitated TIMP-2 than that
of cells expressing higher levels of TIMP-2. These results
suggest that in cells expressing a low level of TIMP-2, the TIMP-
2 stabilizes both TIMP-2-bound and TIMP-2-free MT1-MMP.
To confirm this, a TIMP-2-binding experiment was carried
out using fluorescence-labeled TIMP-2 (Fig. 2a). Because MT1-
MMP is protected from autodegradation by the MMP inhibitor
BB94 in its TIMP-2-free form (Fig. 2b), binding of labeled
TIMP-2 was highest in cells transfected with MT1-MMP plasmid
alone in the presence of BB94. Binding of labeled TIMP-2 was
decreased by cotransfection of TIMP-2 plasmid in proportion to
the transfected TIMP-2 levels in the presence of BB94. This
suggests that TIMP-2 coexpressed with MT1-MMP in the presence
of BB94 may bind to MT1-MMP. Cell-surface biotinylation
and immunoprecipitation experiments confirmed the binding of
TIMP-2 with MT1-MMP in cotransfected cells in the presence
of BB94 (Fig. 2c). In the absence of BB94, binding of labeled
TIMP-2 to the cells transfected with MT1-MMP plasmid alone was
low. Binding of labeled TIMP-2 was enhanced by cotransfection
of a small amount of TIMP-2 plasmid relative to MT1-MMP
plasmid, but this was attenuated by the cotransfection of higher
Fig. 1. Cell-surface membrane-type (MT) 1-matrix metalloproteinase (MMP) and tissue inhibitor of metalloproteinase-2. (a) The expression
plasmid for MT1-MMP-FLAG (700 ng) was cotransfected with the indicated amounts of tissue inhibitor of metalloproteinase-2 plasmid into 293T
cells. At 48 h after transfection, cells were labeled with biotin, and were analyzed as described in ‘Materials and Methods’. Cell-surface MT1-MMP
and tissue inhibitor of metalloproteinase-2 (TIMP-2) coprecipitated with MT1-MMP were detected with IRDye 800-conjugated streptavidin (middle
panel), whereas MT1-MMP latent and active forms were both detected with anti-FLAG M2 antibody labeled with Alexa Fluor 680 (left upper
panel). Aliquots of cell lysates were examined for the expression of TIMP-2 by western blotting using anti-TIMP-2 antibody (left lower panel).
Merged 800 and 680 signals are shown in the right panel. NS, non-specific band. (b) Cell-surface MT1-MMP levels and the ratio of TIMP-2 to MT1-
MMP signal measured from the middle panel are shown. The highest MT1-MMP level (175 ng) and TIMP-2/MT1-MMP ratio (1400 ng) were
arbitrarily set to 1, and the levels of other transfections were adjusted accordingly. The data represent one of three different experiments showing
similar results.
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amounts of TIMP-2 plasmid. This confirms that MT1-MMP on
the surface of cells expressing a low level of TIMP-2 is partly
free from TIMP-2.
Effect of TIMP-2 on pro-MMP-2 activation. The effect of TIMP-2
expression on MT1-MMP-mediated pro-MMP-2 activation and the
gelatin-degrading activity of activated MMP-2 was examined.
Incubation of pro-MMP-2 with the cells transfected with MT1-
MMP plasmid alone resulted in a faint conversion from latent
to active MMP-2, which was enhanced by the cotransfection
of TIMP-2 plasmid dependent on the plasmid concentration
(Fig. 3a). Gelatin was digested most intensively by MMP-2
activated by the cells cotransfected with MT1-MMP and 25 ng
TIMP-2 plasmids, where the level of active MMP-2 was lower
than in cells cotransfected with larger amounts of TIMP-2
plasmid. Conversion to active MMP-2 was most effective in
cells cotransfected with MT1-MMP and 50 ng or more TIMP-2
plasmids; however, MMP-2 activated by those cells showed
lower gelatin-degrading activity. Degradation of gelatin by the cells
or the supernatant was suppressed by either TIMP-1 or TIMP-2,
indicating that gelatin degradation is mediated by MMP-2 and not
MT1-MMP (Fig. 3b). These results suggest that only MT1-MMP,
a part of which is bound by TIMP-2, processed pro-MMP-2 to
Fig. 2. Binding of tissue inhibitor of metalloproteinase-2 (TIMP-2) to the cells expressing membrane-type (MT) 1-matrix metalloproteinase (MMP).
(a) Control plasmid or expression plasmid for MT1-MMP (50 ng) was cotransfected with the indicated amounts of TIMP-2 plasmid into 293T cells
cultured in 48-well plates. Cells were cultured in the presence or absence of 1 µM BB94 for 48 h, and then the TIMP-2 binding experiment was
carried out as described in ‘Materials and Methods’. Binding of Alexa Fluor 680-labeled TIMP-2 was monitored using an Odyssey IR imaging system
(upper panel) and relative fluorescence intensity is shown (lower panel). The fluorescence intensity obtained from the cells trasnfected with MT1-
MMP plasmid alone (lane 0) in the presence of BB94 was arbitrarily set to 1, and the levels of other transfections were adjusted accordingly. The
data represent one of four different experiments showing similar results. (b) Cell lysates from the above transfected cells were examined for the
expression of MT1-MMP and TIMP-2 by western blotting using anti-MT1-MMP and -TIMP-2 antibodies, respectively. (c) The expression plasmid for
MT1-MMP-FLAG (700 ng) was cotranfected with TIMP-2 plasmid (1400 ng) in the presence or absence of BB94, and cell-surface biotinylated
TIMP-2 coprecipitated with MT1-MMP was detected as described in Fig. 1. Note that TIMP-2 was coprecipitated with MT1-MMP from both cells
treated and untreated with BB94.
Fig. 3. Effect of tissue inhibitor of metalloproteinase-2 (TIMP-2) on matrix metalloproteinase (MMP)-2 activation by membrane-type (MT) 1-MMP.
(a) Control plasmid or expression plasmid for MT1-MMP (100 ng) was cotransfected with the indicated amounts of TIMP-2 plasmid into 293T cells
cultured in 48-well plates in duplicate. At 48 h after transfection, cells were incubated with MMP-2 for 1 h. Then, supernatants and cells were
analyzed by gelatin zymography (upper panel) and for gelatin-degradation activity (lower panel) as described in ‘Materials and Methods’. (b) 293T
cells transfected with control plasmid or expression plasmids for MT1-MMP (100 ng) and TIMP-2 (25 ng) were incubated with MMP-2, and gelatin
degradation was examined as above in the presence or absence of 1 µg/mL TIMP-1 or TIMP-2. (c) 293T cells were transfected with control plasmid
or expression plasmids for MT1-MMP (100 ng) and TIMP-2 (25 ng) as indicated, and were incubated with labeled gelatin for 1 h at 48 h after
transfection.
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generate TIMP-2-free active MMP-2. At higher TIMP-2 concen-
trations, pro-MMP-2 was still efficiently converted to active form
by MT1-MMP; however, this MMP-2 was inactive, probably
due to binding of TIMP-2. In order to confirm that gelatin
degradation is not mediated by MT1-MMP but by MMP-2, cells
transfected with MT1-MMP alone or cotransfected with MT1-
MMP and TIMP-2 were incubated directly with gelatin (Fig. 3c).
These cells did significantly degrade gelatin.
Effect of TIMP-2 on cleavage of MT1-MMP substrates. The effect
of TIMP-2 expression on cleavage of the MT1-MMP substrates
testican-1 and syndecan-1 was examined. Testican-1-FLAG
incubated with cells transfected with MT1-MMP was cleaved
efficiently by the cells transfected with MT1-MMP without any
TIMP-2 (Fig. 4). Transfected TIMP-2 did not show any effect at
low concentrations but suppressed testican-1 cleavage at higher
concentrations. Syndecan-1 was previously shown to be cleaved
at the G82–L83 and G245–L246 peptide bonds by MT1-MMP.(14)
Shedding of syndecan-1 was stimulated by transfection of MT1-
MMP plasmid alone, and this was suppressed by cotransfection
of TIMP-2 in proportion to TIMP-2 plasmid concentration (Fig. 5).
Shedding of syndecan-1 and cleavage of testican-1 were inhibited
by TIMP-2 but not by TIMP-1, confirming the involvement
of MT1-MMP.
Discussion
The evaluation of TIMP-2 level in human tumor tissues is still
controversial, and additional research is needed to elucidate
further the roles of TIMP-2 in tumor tissues. MT1-MMP
turnover occurs through autodegradation and endocytosis
depending on cell type.(18–22) Because 293T cells synthesize low
levels of TIMP-2,(23) turnover of cell-surface MT1-MMP is high
due to autodegradation and cell-surface levels are low (Fig. 1).
Activation of pro-MMP-2 is initiated through a tri-molecular
complex composed of MT1-MMP, TIMP-2 and pro-MMP-2,
and TIMP-2-free MT1-MMP adjacent to this complex cleaves
the amino-terminus of pro-MMP-2 to generate the activation
intermediate form.(3) However, it is not clear how the TIMP-2-
bound and TIMP-2-free forms of MT1-MMP localize adjacently
on the cell surface. We demonstrate here for the first time that
low levels of TIMP-2 increased not only the TIMP-2-bound
form but also the free form of MT1-MMP on the cell-surface.
MT1-MMP forms dimers or oligomers through its hemopexin
domain,(24) and TIMP-2-free MT1-MMP in the oligomer is
thought to be subjected to autodegradation by adjacent TIMP-2-
free MT1-MMP. We conclude that TIMP-2-bound MT1-MMP
in the oligomer may interfere with mutual autodegradative
interactions between TIMP-2-free MT1-MMP molecules.
The model of MT1-MMP substrate determination by TIMP-2
is shown in Fig. 6. The optimal TIMP-2 levels for pro-MMP-2
activation allowed partial TIMP-2 binding of MT1-MMP
(Fig. 1), maximum binding of alexa–TIMP-2 to MT1-MMP in
the absence of BB-94 (Fig. 2), and maximal MMP-2 gelatin-
degrading activity (Fig. 3). Lower levels did not protect MT1-
MMP sufficiently from degradation (Fig. 1), and higher levels
allowed pro-MMP-2 processing, but presumably blocked the
MMP-2 activity (Fig. 3). It should be emphasized that TIMP-
2-free MT1-MMP shows the most active proteolytic activity,
Fig. 4. Effect of tissue inhibitor of
metalloproteinase-2 (TIMP-2) on testican-1
cleavage by membrane-type (MT) 1-matrix
metalloproteinase (MMP). Testican-1-FLAG sample
was incubated with 293T cells mock-transfected
or cotransfected with MT1-MMP (700 ng) and
indicated amounts of TIMP-2 plasmid for 3 h.
Cleavage of testican-1-FLAG was analyzed by
western blotting using anti-FLAG M2 antibody
(left panel). Testican-1-FLAG sample was incub-
ated with cells mock-transfected or transfected
with MT1-MMP plasmid in the presence or
absence of TIMP-1 or TIMP-2 (1 µg/mL) for 3 h,
and was analyzed as above (right panel).
Fig. 5. Effect of tissue inhibitor of metalloproteinase-
2 (TIMP-2) on syndecan-1 shedding by membrane-
type (MT) 1-matrix metalloproteinase (MMP). (a)
Expression plasmid for syndecan-1 was cotrans-
fected with control plasmid (lane –) or MT1-MMP
plasmid and indicated amount of TIMP-2 plasmid
into 293T cells, and the culture medium was
replaced with serum-free Dulbecco’s Modified
Eagle Medium (DMEM) at 48 h after transfection.
Medium was harvested after 12 h, and was
analyzed for shed syndecan-1 by dot blot analysis
using anti-syndecan-1 antibody. (b) Cells cotrans-
fected with syndecan-1 and MT1-MMP plasmids
were cultured in serum-free DMEM in the presence
or absence of TIMP-1 or TIMP-2 (1 µg/mL), and
shed syndecan-1 was analyzed as above. The data
represent one of three different experiments
showing similar results. The highest shed syndecan-
1 level for each experiment was arbitrarily set
to 1, and the levels of other transfections were
adjusted accordingly.
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which in turn induces rapid turnover of itself due to auto-
degradation. Thus, the cell-surface active MT1-MMP level is very
low in the absence of MT1-MMP inhibitor, such as TIMP-2 and
BB94 (Figs 1,2), but it still cleaves testican-1 and syndecan-1
most effectively (Figs 4,5). MT1-MMP that has escaped auto-
degradation through TIMP-2 binding appears inactive against
direct substrates for MT1-MMP. Pro-MMP-2 activation could be
achieved by MT1-MMP at a wide range of TIMP-2 levels, but
gelatin-degrading activity was only seen in a limited range (Fig. 3).
This is consistent with the previous report using BS-C-1 cells
infected with recombinant vaccinia viruses expressing MT1-
MMP and TIMP-2.(25) Tri-molecular complex formation may be
a dynamic process in which TIMP-2 may transiently interact with
MT1-MMP, pro-MMP-2 and activated MMP-2 dependent on its
concentration. Interaction of pro-MMP-2 with MT1-MMP bound
to TIMP-2 may cause partial replacement of TIMP-2 to generate
TIMP-2-free MT1-MMP, which in turn processes pro-MMP-2.
Activated MMP-2 is then inactivated by binding to TIMP-2.
Two populations of TIMP-2 binding sites were reported on the
membrane of concanavalin A-treated fibroblasts, one sensitive
and the other insensitive to synthetic hydroxamate inhibitors.(26) In
our transfected 293T cell experimental system, TIMP-2 binding
was totally dependent on the level of TIMP-2-free MT1-MMP on
the cell surface (Fig. 2). Pretreatment of MT1-MMP-expressing
cells with BB94 protected TIMP-2-free MT1-MMP from auto-
degradation and labeled TIMP-2 could bind to MT1-MMP by
replacing BB94 (Fig. 2b). BB94 did not inhibit complex for-
mation between MT1-MMP and TIMP-2 in cotransfected cells
(Fig. 2c), which accounts for the reduced binding of labeled
TIMP-2 by cotransfection of TIMP-2 plasmid in proportion to
the expressed TIMP-2 levels in the presence of BB94. The idea
that TIMP-2 replaces BB94 which binds to MT1-MMP is
consistent with the previous report of synthetic MMP inhibitors
stimulating TIMP-2-dependent MMP-2 activation by MT1-
MMP.(19) It should be noticed that excess BB94 in the binding
reaction inhibited binding of labeled TIMP-2 (data not shown);
however, it can not release TIMP-2 that is already bound to MT1-
MMP. In contrast, TIMP-2 can replace BB94 bound to cell-surface
MT1-MMP unless BB94 exists in excess in culture.
Thus, TIMP-2 concentration dictates MT1-MMP substrate
choice. In the absence of TIMP-2 and at low TIMP-2 concentra-
tions, MT1-MMP cleaves testican-1 and syndecan-1 directly. A
variety of substrates for MT1-MMP were reported other than
ECM components, such as adherence molecules, cytokines and
growth factors, and cell surface receptors.(5) MT1-MMP plays
essential roles in not only tumor invasion and metastasis but
Fig. 6. Model of membrane-type (MT) 1-matrix
metalloproteinase (MMP) substrate determination
by tissue inhibitor of metalloproteinase-2 (TIMP-
2). (a) At low or no TIMP-2, TIMP-2-free MT1-
MMP digests its own substrates such as testican-1,
syndecan-1 and presumably collagens, but it does
not activate pro-MMP-2. TIMP-2-free MT1-MMP
shows the most active proteolytic activity, which
in turn causes rapid turnover due to intensive
autodegradation. (b) At appropriate levels of
TIMP-2, binding of TIMP-2 protects MT1-MMP
(TIMP-2-bound and -free) from autodegradation,
and the complex serves as a receptor for pro-MMP-
2, which is then cleaved by adjacent TIMP-2-free
MT1-MMP to generate active MMP-2. Because a
part of MT1-MMP binds to TIMP-2, it digests its
own substrates less effectively. (c) When MT1-MMP
is saturated with TIMP-2, pro-MMP-2 may trans-
iently replace TIMP-2 to generate TIMP-2-free
MT1-MMP, which then cleaves pro-MMP-2, but
activated MMP-2 is finally blocked by TIMP-2.
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also tumor cell growth in a three-dimensional matrix composed
largely of type I collagen or cross-linked fibrin.(27) These multi-
functions of MT1-MMP appear to be involved in the regulation
of various events taking place at the cell–ECM interface. In
higher concentrations of TIMP-2, MT1-MMP is involved in
ECM degradation through the activation of MMP-2, possibly as
a resolving wave to remove degradation byproducts (denatured
collagens) after direct ECM degradation. It remains to be
explored which function of MT1-MMP is most associated with
malignancy of tumors.
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